On Day 1, treatment begins after you have been assigned to receive either empagliflozin tablets or placebo tablets. Placebo tablets look like the actual medication but contain no active ingredient.

The assignment to either empagliflozin or placebo is done randomly, and neither you nor your doctor will know which treatment you are receiving during this period. This is called a double-blind phase.

You will take the tablets by mouth as instructed by the study doctor.

Your current kidney disease treatment will continue unchanged during the study, as long as the dose has been stable for 30 days before starting.

You will continue taking your assigned tablets daily by mouth.

During this time, the study team will monitor how your kidneys are functioning by measuring your eGFR, which stands for estimated glomerular filtration rate. This is a measure of how well your kidneys are filtering waste from your blood.

You will attend scheduled visits as directed by the study team.

At Week 24, several measurements will be taken to evaluate how the treatment has affected your condition.

The study team will measure changes in your UACR, which stands for urine albumin-to-creatinine ratio. This test shows how much protein is leaking into your urine, which is a sign of kidney damage.

Your urine glucose levels will be measured. This shows how much sugar is present in your urine.

Your UPCR, which stands for urine protein-to-creatinine ratio, will also be measured. This is another way to check for protein in your urine.

A blood sample will be taken before your daily dose to measure the amount of empagliflozin in your blood.

The study team will review any side effects or health problems you may have experienced since Day 1.

After Week 24, you may continue into an open-label extension phase. During this phase, both you and your doctor will know that you are receiving empagliflozin, not placebo.

If you were receiving placebo during the first 24 weeks, you will now switch to empagliflozin tablets taken by mouth.

If you were already receiving empagliflozin, you will continue taking it.

You will continue taking empagliflozin tablets daily by mouth during the open-label extension.

At Week 26, another blood sample will be taken before your daily dose to measure empagliflozin levels in your blood.

The study team will continue to monitor your kidney function by measuring eGFR over time.

Regular assessments will be conducted to check for any side effects or health problems.

When you complete the treatment phase, you will stop taking the study tablets.

For 7 days after your last dose, the study team will continue to monitor you for any side effects. This period is called the residual effect period.

A final assessment will be conducted to evaluate your overall health and kidney function.